Skip to Main Content (Press Enter)
×
Home
Corsi
Insegnamenti
Professioni
Persone
Pubblicazioni
Strutture
Terza Missione
Attività
Competenze
IT
EN
☰
UNI-FIND
|
UNI-FIND
uninsubria.it
IT
EN
×
Home
Corsi
Insegnamenti
Professioni
Persone
Pubblicazioni
Strutture
Terza Missione
Attività
Competenze
☰
Pubblicazioni
THE LANCET ONCOLOGY
Rivista
Codice:
E098908
ISSN:
1470-2045
Dati Generali
Dati Generali
Pubblicazioni (12)
Pulisci
Ordina Pubblicazioni:
ascendente
decrescente
2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
Articolo
2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19
Articolo
Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial
Articolo
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial
Articolo
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
Articolo
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
Articolo
Malignant ectomesenchymoma of the nasal cavity
Articolo
Malignant pleural mesothelioma: time for translational research
Articolo
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial
Articolo
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
Articolo
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study
Articolo
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
Articolo
No Results Found
«
‹
{pageNumber}
›
»
{startItem} - {endItem} di {itemsNumber}
5 per pagina
10 per pagina
30 per pagina
vedi tutti
